Cargando…

The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders

OBJECTIVES: This study aimed to identify the barriers and facilitators to improve the use of health technology assessment (HTA) for the selection of medicines listed in the e-Catalogue and the national formulary in Indonesia. METHODS: Semi-structured interviews were conducted to collect qualitative...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wasir, Riswandy, Irawati, Sylvi, Makady, Amr, Postma, Maarten, Goettsch, Wim, Feenstra, Talitha, Buskens, Erik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6881021/ https://www.ncbi.nlm.nih.gov/pubmed/31774854 http://dx.doi.org/10.1371/journal.pone.0225626

Ejemplares similares

Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia
por: Wasir, Riswandy, et al.
Publicado: (2019)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs
por: Callenbach, Marcelien H. E., et al.
Publicado: (2022)

Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies
por: Bloem, Lourens T., et al.
Publicado: (2021)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe
por: Kawalec, Paweł, et al.
Publicado: (2016)

Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
por: Schelleman, Hedi, et al.
Publicado: (2015)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis
por: Dahmani, Hajer, et al.
Publicado: (2023)

A Comparison of Reimbursement Recommendations by European HTA Agencies: Is There Opportunity for Further Alignment?
por: Allen, Nicola, et al.
Publicado: (2017)

The role of stakeholder involvement in the evolving EU HTA process: Insights generated through the European Access Academy’s multi-stakeholder pre-convention questionnaire
por: Van Haesendonck, Lauren, et al.
Publicado: (2023)

Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member States
por: Vogler, Sabine, et al.
Publicado: (2011)

Physician pricing and health insurance reimbursement
por: Yett, Donald E., et al.
Publicado: (1983)

Stratified Medicine and Reimbursement Issues
por: Fugel, Hans-Joerg, et al.
Publicado: (2012)

Cost-Effectiveness of Four Tobacco Control Interventions in Mongolia
por: Tuvdendorj, Ariuntuya, et al.
Publicado: (2023)

Use of Social Media in the Assessment of Relative Effectiveness: Explorative Review With Examples From Oncology
por: Kalf, Rachel RJ, et al.
Publicado: (2018)

Pricing and reimbursement of novel oncology drugs in Sweden
por: Haglund, Mattias, et al.
Publicado: (2014)

The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?
por: Vogler, Sabine, et al.
Publicado: (2015)

The reimbursement for expensive medicines: stakeholder perspectives on the SMA medicine nusinersen and the Dutch Coverage Lock policy
por: Scheijmans, Féline E. V., et al.
Publicado: (2022)

Informing policy makers on the efficiency of population level tobacco control interventions in Asia: A systematic review of model-based economic evaluations
por: Tuvdendorj, Ariuntuya, et al.
Publicado: (2020)

More than cost‐effectiveness? Applying a second‐stage filter to improve policy decision making
por: Kan, Kaying, et al.
Publicado: (2021)

Burden and Cost of Anterior Cruciate Ligament Reconstruction and Reimbursement of Its Treatment in a Developing Country: An Observational Study in Indonesia
por: Deviandri, Romy, et al.
Publicado: (2022)

Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration
por: Kamphuis, Bregtje W., et al.
Publicado: (2021)

Pricing and reimbursement of orphan drugs: the need for more transparency
por: Simoens, Steven
Publicado: (2011)

Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017)

Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries
por: Kawalec, Paweł, et al.
Publicado: (2017)

The timelines for the price and reimbursement authorization in Italy 2018–2020
por: Gallo, Valentina, et al.
Publicado: (2022)

Smoking-attributable burden of lung cancer in Mongolia a data synthesis study on differences between men and women
por: Tuvdendorj, Ariuntuya, et al.
Publicado: (2020)

HB-HTA as an implementation problem in Polish health policy
por: Gałązka-Sobotka, Małgorzata, et al.
Publicado: (2021)

Key factors influencing the prescribing of statins: a qualitative study among physicians working in primary healthcare facilities in Indonesia
por: Irawati, Sylvi, et al.
Publicado: (2020)

Impact of price and non-price policies on household cigarette consumption and nutrient intake in smoking-tolerant Indonesia
por: Djutaharta, Triasih, et al.
Publicado: (2021)

The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
por: Mordi, Dumebi O, et al.
Publicado: (2015)

Challenges and Opportunities for Companies to Build HTA/Payer Perspectives Into Drug Development Through the Use of a Dynamic Target Product Profile
por: Wang, Ting, et al.
Publicado: (2022)

Reimbursement of pharmaceuticals: reference pricing versus health technology assessment
por: Drummond, Michael, et al.
Publicado: (2010)

Approval, reimbursement and pricing of high-cost cancer medicines in Australia
por: Vitry, Agnes
Publicado: (2015)

The reimbursement coverage decisions and pricing rules for medical devices in Taiwan
por: Tsai, Hsin-Yi, et al.
Publicado: (2022)

Reporting reimbursement price decisions for onco-hematology drugs in Spain
por: Elvira, David, et al.
Publicado: (2023)

Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_2bm0a018e4qv5re3ras5rpvhbk